glp-1 agonists weight loss side effects Part 2 of a 3-Part Series; Medications for Glucagon-like Receptor-1 agonists for obesity:

These areas are responsible for a variety of critical functions that often are affected by Alzheimer's disease, including memory, language and decision-making

GLP-1 RAs have been shown to result in increased residual gastric contents (RGCs) in patients undergoing EGDs and poor Boston Bowel Preparation Scores (BBPSs) in those undergoing colonoscopies

2 Department of Clinical Research, University of Basel, Basel, Switzerland

Glucagon-like peptide-1 receptor agonists and safety in the preconception period

Future Outlook The GLP-1 Drug Market size is projected to reach USD 42.0 billion by 2035, growing at a CAGR of 13.17%, driven by increasing diabetes prevalence, rising obesity rates, and advancements in drug formulations

Source: Heymsfield et al., JAMA, 2021